Long-Term Results Underscore Value of Early MS Treatment Long-Term Results Underscore Value of Early MS Treatment

An 11-year follow-up of patients with MS treated with interferon beta-1b in the BENEFIT trial shows continued improved outcomes among those treated early. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news